Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Platelets

• Publication date

  2010-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/09537100903521611PMID 20163197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Laropiprant in Combination With Extended‐Release Niacin Does Not Alter Urine 11‐Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

  2009cited by this paper
• Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.

  2008cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

  2008cited by this paper
• SAFETY PROFILE OF EXTENDED-RELEASE NIACIN/LAROPIPRANT IN PATIENTS WITH DYSLIPIDEMIA

  2008cited by this paper
• Effects of Dexibuprofen on Platelet Function in Humans: Comparison with Low-dose Aspirin

  2007cited by this paper
• The pharmacokinetics and disposition of MK-0524, a Prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys

  2007cited by this paper
• Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

  2007cited by this paper
• Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

  2007cited by this paper
• Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

  2007cited by this paper
• Nicotinic Acid-Induced Flushing Is Mediated by Activation of Epidermal Langerhans Cells

  2006cited by this paper
• The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.

  2006cited by this paper
• Abstract 1634: Effects of the DP1-receptor Antagonist MK-0524 on Nicotinic Acid-Induced Flushing in Lipid Clinic Patients

  2006cited by this paper
• Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

  2006cited by this paper
• Langerhans cells release prostaglandin D2 in response to nicotinic acid.

  2006cited by this paper
• Glutaraldehyde-Fixed Bioprosthetic Heart Valve Conduits Calcify and Fail From Xenograft Rejection

  2006cited by this paper
• Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review

  2005cited by this paper
• Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.

  2004cited by this paper
• The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

  2003cited by this paper
• The pharmacokinetics of the interstitial space in humans

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

  2001cited by this paper
• Niacin dosing: Relationship to benefits and adverse effects

  2000cited by this paper
• Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects

  1998cited by this paper
• A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.

  1998cited by this paper
• Platelet prostanoid receptors.

  1996cited by this paper
• Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.

  1992cited by this paper
• Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.

  1991cited by this paper
• Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.

  1989cited by this paper
• Prostaglandins and nicotinate‐provoked increase in cutaneous blood flow

  1985cited by this paper
• Is cutaneous flushing prostaglandin mediated?

  1981cited by this paper
• DOES T4-TOXICOSIS EXIST ?

  1975cited by this paper

• Jefferson Digital

  2022cites this paper
• The lipid paradox in neuroprogressive disorders: Causes and consequences.

  2021cites this paper
• Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system

  2018cites this paper
• EDITORIAL: Repurposing Niacin as Antiplatelet Drug?

  2016cites this paper
• Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

  2015cites this paper
• Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

  2014cites this paper
• Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia

  2014cites this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cites this paper
• The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin

  2014influential citation
• The role of niacin in lipid-lowering treatment: are we aiming too high?

  2013cites this paper
• Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis[S]

  2013cites this paper
• NIACIN AND NIACIN / LAROPIPRANT COMBINATION: OPENING NEW HOPES FOR DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES WITH FEW NOVEL ACTIONS

  2013cites this paper
• HDL functionality and LDL quality : the influence of obesity, obstructive sleep apnoea and pharmacological intervention

  2013cites this paper
• Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

  2012cites this paper
• Safety and tolerability of extended-release niacin with laropiprant

  2012cites this paper
• Effects of nicotinic acid on endothelial cells and platelets.

  2012cites this paper
• Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

  2012cites this paper
• Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

  2012cites this paper
• Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters

  2011cites this paper
• The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

  2011cites this paper
• Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.

  2011cites this paper
• Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease

  2010cites this paper